Synthetic Lethality Screening for Selective ADPKD Cyst Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autosomal dominant polycystic kidney disease (ADPKD) are burdensome, costly, and have modest efficacy, with no approved cure, and there is a need for compounds that can selectively target and reduce cyst burden while sparing healthy kidney tissue.
Innovation Solution
A cell-based high-throughput screening assay identifies compounds using the concept of synthetic lethality, where test compounds are contacted with PKD1-deficient or PKD2-deficient cells, and those reducing their viability more than isogenic control cells are identified, potentially reducing cyst number and size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ADPKD are used, then disease progression is slowed, but treatment burden and cost increase while efficacy remains modest
Solution Approach 1:
The treatment approach is segmented by genotype, targeting specific molecular pathways (PKD1 or PKD2 mutations) with tailored compound interventions. This segmentation enables precise therapeutic action on cyst-lining cells while sparing healthy tissue, thereby improving efficacy without increasing overall treatment burden for the patient population.
Solution Approach 2:
The synthetic lethality mechanism enables the treatment to work through the disease's own pathological mechanism - the mutated PKD1/PKD2 genes create vulnerability that the compound exploits. The cyst-lining cells' inherent genetic defect becomes the target, allowing the treatment to leverage the disease process itself rather than opposing it, improving efficacy without requiring complex external management.
2Object-affected harmful factors
If compounds are designed to target cyst-lining cells selectively, then cyst burden is reduced, but specificity and precision requirements increase
Solution Approach 1:
The compound exhibits local quality by having different effects on different cell types - it is selectively toxic to cyst-lining cells with PKD1/PKD2 mutations while being benign to healthy kidney cells. This spatial and cellular specificity is achieved through the synthetic lethality mechanism, where the compound's action is contingent on the presence of the specific genetic mutation, thereby reducing cyst burden without requiring extreme manufacturing precision.
Solution Approach 2:
The compound's effectiveness is parameter-dependent, working specifically under the condition of PKD1/PKD2 mutation presence. The synthetic lethality approach changes the parameter space by exploiting the genetic vulnerability - the compound only exerts its cytotoxic effect when the specific molecular target (mutated PKD protein) is present, providing automatic specificity without requiring complex molecular engineering.
3Productivity
If high-throughput screening is used to identify compounds, then compound discovery speed increases, but assay complexity and resource requirements increase
Solution Approach 1:
The assay extracts only the essential feature needed for screening - cell viability in the presence of PKD1/PKD2 mutations - and removes unnecessary complexity. By focusing solely on detecting differential viability between mutant and wild-type cells, the assay achieves high throughput without requiring complex multi-parameter measurements or sophisticated instrumentation, thereby maintaining simplicity while enabling rapid compound discovery.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present application relates to a process for identifying a compound useful for treating autosomal dominant polycystic kidney disease (ADPKD) and compounds for use in the treatment of ADPKD.